PLGRKT

Across TCGA pan-cancer cohorts, PLGRKT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLGRKT data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLGRKT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLGRKT expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where PLGRKT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.291	0.537	.002	21	view →
LUAD	OS	Median	III,IV	0.869	0.330	.006	20	view →
UCEC	DFS	Tertile	II,III,IV	0.617	1.000	.024	14	view →
GBM	DFS	Quartile	All	0.467	0.266	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLGRKT–PDAC (DFS)

Open the PDAC breakdown →